Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma

Oral Oncology

Volumn 46, Issue 5, 2010, Pages 336-342

  De Boeck, Astrid ^a   Narine, Kishan ^b   De Neve, Wilfried ^a   Mareel, Marc ^a   Bracke, Marc ^a   De Wever, Olivier ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

Angiogenesis; Immunomodulation; Invasion; Myofibroblast; Oral cancer; Stromal cells

Indexed keywords

ANGIOGENESIS; BONE MARROW; CANCER GROWTH; CANCER RECURRENCE; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MESENCHYMAL STEM CELL; METASTASIS; MYOFIBROBLAST; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STROMA;

CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MESENCHYMAL STEM CELLS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77950957772     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.01.016     Document Type: Review

References (110)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 4 (2009) 225-249
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
3. Haddad R.I., and Shin D.M. Recent advances in head and neck cancer. N Engl J Med 359 11 (2008) 1143-1154
4. Weber F., Xu Y.M., Zhang L., et al. Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA 297 2 (2007) 187-195
5. Teh M.T., Tilakaratne W.M., Chaplin T., et al. Fingerprinting genomic instability in oral submucous fibrosis. J Oral Pathol Med 37 7 (2008) 430-436
6. Chung C.H., Parker J.S., Karaca G., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5 5 (2004) 489-500
7. He Y.K., Zeng Q., Drenning S.D., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90 14 (1998) 1080-1087
8. Ang K.K., Berkey B.A., Tu X.Y., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 24 (2002) 7350-7356
9. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 4 (2005) 301-311
10. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11 1 (2010) 21-28
11. Gregoire V., De Neve W., Eisbruch A., Lee N., Van den Weyngaert D., and Van Gestel D. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 12 5 (2007) 555-564
12. Zielske S.P., Livant D.L., and Lawrence T.S. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 75 3 (2009) 843-853
13. Klopp A.H., Spaeth E.L., Dembinski J.L., et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 67 24 (2007) 11687-11695
14. De Wever O., Demetter P., Mareel M., and Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123 10 (2008) 2229-2238
15. Madani I., De Neve W., and Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis?. Bull Cancer 95 3 (2008) 292-300
16. Dennis J.E., and Caplan A.I. Bone marrow mesenchymal stem cells. In: Sell S. (Ed). Stem cells handbook (2004), Humana Press, Totowa 107-118
17. Friedenstein AJ. Determined and inducible osteogenic precursor cells. In: Katherine Elliott DWF, editor. Ciba foundation symposium 11 - hard tissue growth, repair and remineralization; 1973. p. 169-85.
18. Caplan A.I. Mesenchymal stem cells. J Orthop Res 9 5 (1991) 641-650
19. Dominici M, Blanc KL, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006;8(4):315-7.
20. Majd H., Wipff P.-J., Buscemi L., et al. A novel method of dynamic culture surface expansion improves mesenchymal stem cell proliferation and phenotype. Stem Cells 27 1 (2009) 200-209
21. Le Douarin N.M., Creuzet S., Couly G., and Dupin E. Neural crest cell plasticity and its limits. Development 131 19 (2004) 4637-4650
22. Couly G.F., Coltey P.M., and Le Douarin N.M. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. Development 117 2 (1993) 409-429
23. Young H.E., and Black Jr. A.C. Adult stem cells. Anat Rec A Discov Mol Cell Evol Biol 276 1 (2004) 75-102
24. Takashima Y., Era T., Nakao K., et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129 7 (2007) 1377-1388
25. Nikitina N., Sauka-Spengler T., and Bronner-Fraser M. Dissecting early regulatory relationships in the lamprey neural crest gene network. Proc Natl Acad Sci USA 105 51 (2008) 20083-20088
26. Mendes S.C., Robin C., and Dzierzak E. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 132 5 (2005) 1127-1136
27. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 5411 (1999) 143-147
28. Lindroos B., Mäenpää K., Ylikomi T., Oja H., Suuronen R., and Miettinen S. Characterisation of human dental stem cells and buccal mucosa fibroblasts. Biochem Biophys Res Commun 368 2 (2008) 329-335
29. Shi S., and Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 18 4 (2003) 696-704
30. Pierdomenico L., Bonsi L., Calvitti M., et al. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation 80 6 (2005) 836-842
31. Janjanin S., Djouad F., Shanti R.M., et al. Human palatine tonsil: a new potential tissue source of multipotent mesenchymal progenitor cells. Arthritis Res Ther 10 4 (2008) R83
32. Sonoyama W., Liu Y., Yamaza T., et al. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J Endod 34 2 (2008) 166-171
33. Tondreau T., Meuleman N., Delforge A., et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 23 8 (2005) 1105-1112
34. Meirelles L.D.S., Chagastelles P.C., and Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119 11 (2006) 2204-2213
35. Lehn C.N., and Rapoport A. The desmoplastic lymph node reaction as a prognostic factor of cancer of the tongue and floor of the mouth. Sao Paulo Med J 112 3 (1994) 591-596
36. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3 3 (2008) 301-313
37. Stappenbeck T.S., and Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science 324 5935 (2009) 1666-1669
38. Chamberlain G., Fox J., Ashton B., and Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem cells 25 11 (2007) 2739-2749
39. Lombaert I.M.A., Wierenga P.K., Kok T., Kampinga H.H., deHaan G., and Coppes R.P. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin Cancer Res 12 6 (2006) 1804-1812
40. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9 4 (2009) 239-252
41. Brennan J.A., Mao L., Hruban R.H., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332 7 (1995) 429-435
42. Ragaz J. Comments on kinetics and biology of the residual cancer, and on relevant therapeutic strategies based on these phenomena. Prog Clin Biol Res 354B (1990) 117-139
43. Jones A.S., Hanafi Z.B., Nadapalan V., Roland N.J., Kinsella A., and Helliwell T.R. Do positive resection margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer 74 1 (1996) 128-132
44. Direkze N.C., Hodivala-Dilke K., Jeffery R., et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 64 23 (2004) 8492-8495
45. Ishii G., Sangai T., Oda T., et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 309 1 (2003) 232-240
46. Pries R., Nitsch S., and Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 6 9 (2006) 1195-1203
47. Allen C., Duffy S., Teknos T., et al. Nuclear factor-kB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 13 11 (2007) 3182-3190
48. Koontongkaew S., Amornphimoltham P., and Yapong B. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells. Cell Biol Int 33 2 (2009) 165-173
49. Ponte A.L., Marais E., Gallay N., et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem cells 25 7 (2007) 1737-1745
50. Wang F., Arun P., Friedman J., Chen Z., and Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9 4 (2009) 389-395
51. Ries C., Egea V., Karow M., Kolb H., Jochum M., and Neth P. MMP-2, MTI-MMP, and TMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109 9 (2007) 4055-4063
52. Spaeth E.L., Dembinski J.L., Sasser A.K., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS One 4 4 (2009) e4992
53. Karnoub A.E., Dash A.B., Vo A.P., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 7162 (2007) 557-563
54. Kellermann M.G., Sobral L.M., da Silva S.D., et al. Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol 44 5 (2008) 509-517
55. Nielsen J.D., Moeslund M., Wandall H.H., and Dabelsteen S. Influences of tumor stroma on the malignant phenotype. J Oral Pathol Med 37 7 (2008) 412-416
56. Eisma R.J., Spiro J.D., and Kreutzer D.L. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 109 5 (1999) 687-693
57. Lozito T.P., Kuo C.K., Taboas J.M., and Tuan R.S. Human mesenchymal stem cells express vascular cell phenotypes upon interaction with endothelial cell matrix. J Cell Biochem 107 4 (2009) 714-722
58. Oswald J., Boxberger S., Jørgensen B., et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem cells 22 3 (2004) 377-384
59. Hamou C., Callaghan M.J., Thangarajah H., et al. Mesenchymal stem cells can participate in ischemic neovascularization. Plast Reconstr Surg 123 2 Suppl. (2009) 45S-55S
60. Kinnaird T., Stabile E., Burnett M.S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94 5 (2004) 678-685
61. Potier E., Ferreira E., Andriamanalijaona R., et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 40 4 (2007) 1078-1087
62. Li T.-S., Hamano K., Suzuki K., Ito H., Zempo N., and Matsuzaki M. Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rats. Am J Physiol Heart Circ Physiol 283 2 (2002) H468-H473
63. Beasley N.J.P., Prevo R., Banerji S., et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62 5 (2002) 1315-1320
64. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., and Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2 8 (2002) 573-583
65. Kishimoto K., Sasaki A., Yoshihama Y., Mese H., Tsukamoto G., and Matsumura T. Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol 39 4 (2003) 391-396
66. Tanigaki Y., Nagashima Y., Kitamura Y., Matsuda H., Mikami Y., and Tsukuda M. The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 14 3 (2004) 389-395
67. Conrad C., Niess H., Huss R., et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation 119 2 (2009) 281-289
68. Whiteside T.L. Immunobiology of head and neck cancer. Cancer Metastasis Rev 24 1 (2005) 95-105
69. Jewett A., Head C., and Cacalano N.A. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res. 85 12 (2006) 1061-1073
70. Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 10 (2003) 3837-3844
71. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 312 12 (2006) 2169-2179
72. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57 1 (2003) 11-20
73. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 9 (2003) 3722-3729
74. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 4 (2005) 1815-1822
75. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 10 (2002) 3838-3843
76. Glennie S., Soeiro I., Dyson P.J., Lam E.W.-F., and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105 7 (2005) 2821-2827
77. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 8 (2003) 1208-1213
78. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112 3 (2008) 532-541
79. Augello A., Tasso R., Negrini Simone M., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35 5 (2005) 1482-1490
80. Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107 1 (2006) 367-372
81. Kawashiri S., Tanaka A., Noguchi N., et al. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 31 10 (2009) 1346-1353
82. Lewis M.P., Lygoe K.A., Nystrom M.L., et al. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90 4 (2004) 822-832
83. Vered M, Dobriyan A, Dayan D, et al. Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer Sci in press;101(1):274-80 [doi:10.1111/j.1349-7006.2009.01357].
84. Kojc N., Zidar N., Vodopivec B., and Gale N. Expression of CD34, [alpha]-smooth muscle actin, and transforming growth factor [beta]1 in squamous intraepithelial lesions and squamous cell carcinoma of the larynx and hypopharynx. Hum Pathol 36 1 (2005) 16-21
85. Barth P.J., Schenck zu Schweinsberg T., Ramaswamy A., and Moll R. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch 444 3 (2004) 231-234
86. Ralhan R., Desouza L.V., Matta A., et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7 6 (2008) 1162-1173
87. De Wever O., Pauwels P., De Craene B., et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130 3 (2008) 481-494
88. Muehlberg F.L., Song Y.H., Krohn A., et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 30 4 (2009) 589-597
89. Narine K., De Wever O., Van Valckenborgh D., et al. Growth factor modulation of fibroblast proliferation, differentiation, and invasion: implications for tissue valve engineering. Tissue Eng 12 10 (2006) 2707-2716
90. Liss C., Fekete M.J., Hasina R., Lam C.D., and Lingen M.W. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer 93 6 (2001) 781-785
91. Barcellos-Hoff M., and Dix T. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10 9 (1996) 1077-1083
92. Mishra P.J., Mishra P.J., Humeniuk R., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68 11 (2008) 4331-4339
93. Menon L.G., Picinich S., Koneru R., et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 25 2 (2007) 520-528
94. Haniffa M.A., Collin M.P., Buckley C.D., and Dazzi F. Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica 94 2 (2009) 258-263
95. Knowles L.M., Stabile L.P., Egloff A.M., et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15 11 (2009) 3740-3750
96. Seiwert T.Y., Jagadeeswaran R., Faoro L., et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69 7 (2009) 3021-3031
97. Chiang W.-F., Liu S.-Y., Fang L.-Y., et al. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 44 4 (2008) 325-334
98. Hwang J.H., Shim S.S., Seok O.S., et al. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci 24 4 (2009) 547-554
99. Rehman A.O., and Wang C.Y. SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB. J Biol Chem 283 29 (2008) 19888-19894
100. Chung C.H., Parker J.S., Ely K., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66 16 (2006) 8210-8218
101. Szczepanski M.J., Czystowska M., Szajnik M., et al. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69 7 (2009) 3105-3113
102. Midwood K., Sacre S., Piccinini A.M., et al. Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15 7 (2009) 774-780
103. Zhang W., Matrisian L.M., Holmbeck K., Vick C.C., and Rosenthal E.L. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6 (2006) 52
104. Sudo K., Kanno M., Miharada K., et al. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. Stem Cells 25 7 (2007) 1610-1617
105. Studeny M., Marini F.C., Dembinski J.L., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96 21 (2004) 1593-1603
106. Jeon E.S., Moon H.J., Lee M.J., et al. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem cells 26 3 (2008) 789-797
107. Ball S.G., Shuttleworth C.A., and Kielty C.M. Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39 2 (2007) 379-391
108. Jeon E.S., Moon H.J., Lee M.J., et al. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-{beta}-dependent mechanism. J Cell Sci 119 23 (2006) 4994-5005
109. Emura M., Ochiai A., Horino M., Arndt W., Kamino K., and Hirohashi S. Development of myofibroblasts from human bone marrow mesenchymal stem cells cocultured with human colon carcinoma cells and TGF beta 1. In Vitro Cell Dev Biol Anim 36 2 (2000) 77-80
110. Mareel M., Oliveira M.J., and Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 454 6 (2009) 599-622